Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Fineline Cube Jul 22, 2026
Company Deals

Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market

Fineline Cube Jul 21, 2026
Company Deals Digital

Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics

Fineline Cube Jul 21, 2026
Policy / Regulatory

China Launches 12th Batch of National Drug Procurement with Vonoprazan and Vitamin B6 Drawing Record Competition

Fineline Cube Jul 21, 2026
Company Drug

Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications

Fineline Cube Jul 22, 2026
Company Drug

Junshi Biosciences Receives NMPA Acceptance for Toripalimab Expanded Indication in Resectable Stage II–III NSCLC

Fineline Cube Jul 22, 2026
Company R&D

Takeda Reinforces Takeda Spark Incubator Program with Expanded Partnerships in China

Fineline Cube Nov 30, 2023

Takeda (TYO: 4502) has reportedly renewed and expanded a series of partnerships to bolster its...

Company

Novocure Restructures and Prioritizes Pipeline Amid Anticipated NSCLC Approval

Fineline Cube Nov 30, 2023

Novocure (NASDAQ: NVCR), a Switzerland-based developer of Tumor Treating Fields (TTFields) cancer therapeutic technology that...

Company Drug

AbbVie’s Telisotuzumab-Vedotin Shows Promising Results in NSCLC Phase 2 Trial

Fineline Cube Nov 30, 2023

AbbVie (NYSE: ABBV) has unveiled data from a Phase 2 trial of its potential first-in-class...

Company Deals

Boehringer Ingelheim Partners with Phenomic AI to Target Stroma-Rich Cancers

Fineline Cube Nov 30, 2023

Boehringer Ingelheim (BI), a German pharmaceutical company, has entered into a partnership with Canada’s Phenomic...

Company Drug

Jiangsu Hengrui Receives NMPA Approval for Esophageal Cancer and Breast Cancer Clinical Trials

Fineline Cube Nov 30, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received approval from the National Medical Products...

Company Drug

Asieris Pharmaceuticals’ Hexvix for Bladder Cancer Accepted for Review by China’s NMPA

Fineline Cube Nov 30, 2023

Asieris Pharmaceuticals (SHA: 688176), a specialist in urogenital cancer based in China, has announced that...

Company Drug

Jiangxi Jemincare’s KRAS Inhibitor Earns Breakthrough Designation from China’s CDE for NSCLC

Fineline Cube Nov 30, 2023

The China Center for Drug Evaluation (CDE) website has indicated that Jiangxi Jemincare Group’s proprietary...

Company Deals

Eli Lilly Partners with Prism BioLab to Discover Peptide-Mimicking Small Molecule Inhibitors

Fineline Cube Nov 30, 2023

Eli Lilly and Company (NYSE: LLY) has entered into a partnership with Japan-based biotechnology firm...

Company Drug

Roche’s Mosunetuzumab and AnHeart’s Taletrectinib Poised for Priority Review in China

Fineline Cube Nov 30, 2023

The China Center for Drug Evaluation (CDE) website has indicated that Roche’s (SWX: ROG) Lunsumio...

Policy / Regulatory

China’s CDE Expands Market Approval Services with Two New Regional Windows

Fineline Cube Nov 30, 2023

The China Center for Drug Evaluation (CDE) has announced the establishment of two additional external...

Company Drug

Sinocelltech’s PD-1 Inhibitor SCT-I10A for HNSCC Accepted for NMPA Review

Fineline Cube Nov 30, 2023

Sinocelltech Group Ltd (SHA: 688520), a Chinese biopharmaceutical company, has announced that its market approval...

Company Deals

Bosscome Science & Technology Secures Series A Funding for Precision Medical Navigation Systems

Fineline Cube Nov 30, 2023

Bosscome Science & Technology, a Chongqing-based developer of integrated optical and magnetic navigation systems, has...

Company Policy / Regulatory

NMPA Approves TINGSN Technology’s Disposable Intracardiac Ultrasound Diagnostic Catheter

Fineline Cube Nov 30, 2023

The National Medical Products Administration (NMPA) has granted market approval to TINGSN Technology, a China-based...

Company Drug

Everest Medicines’ Nefecon NDA for IgAN Accepted for Review in South Korea

Fineline Cube Nov 30, 2023

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that the New Drug Application...

Company Digital

ClouDr Partners with Yangtze River Pharmaceutical to Digitize Chronic Disease Marketing

Fineline Cube Nov 30, 2023

Hangzhou Kang Ming Information Technology Co., Ltd, trading as “ClouDr” (HKG: 9955), has entered into...

Company Policy / Regulatory

CAR T-Cell Therapy Stocks Plunge as FDA Investigates Cancer Reports Linked to Treatments

Fineline Cube Nov 30, 2023

Shares of Chimeric Antigen Receptor (CAR) T cell therapy companies plummeted on November 28, 2023,...

Company Deals

Pfizer Enters Strategic Alliance with Guangdong Government to Boost Biomedicine R&D

Fineline Cube Nov 29, 2023

Pfizer (NYSE: PFE), the US pharmaceutical powerhouse, has signed a strategic memorandum of understanding with...

Company Deals

Bayer Partners with Hurdle to Launch Saliva-Based Age Tests in Global E-Commerce

Fineline Cube Nov 29, 2023

Bayer (ETR: BAYN), the German multinational, has announced a strategic collaboration to globally distribute Hurdle’s...

Company Drug

Merck’s V116 Pneumococcal Vaccine Shows Promising Data Against Pfizer’s Prevnar 20

Fineline Cube Nov 29, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has unveiled new data from a late-stage trial...

Policy / Regulatory

China’s Pharma Distribution Market Grows Steadily in 2022, Driven by Retail Sales Surge

Fineline Cube Nov 29, 2023

The Ministry of Commerce (MofCOM) has released its annual statistical review of China’s pharmaceutical distribution...

Posts pagination

1 … 468 469 470 … 698

Recent updates

  • Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II
  • TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal
  • Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications
  • Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody
  • Novo Nordisk Sues Eli Lilly Over Alleged False Advertising of Zepbound and Mounjaro in GLP-1 Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Company Drug

Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications

Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.